Our top pick for
Beginners
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our opinions or reviews. Learn how we make money.
How to buy Alexion Pharmaceuticals stock | $113.57
Own Alexion Pharmaceuticals stock in just a few minutes.
Alexion Pharmaceuticals, Inc is a biotechnology business based in the US. Alexion Pharmaceuticals shares (ALXN) are listed on the NASDAQ and all prices are listed in US Dollars. Alexion Pharmaceuticals employs 3,082 staff and has a trailing 12-month revenue of around USD$5.5 billion.
How to buy shares in Alexion Pharmaceuticals
- Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
- Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
- Search for Alexion Pharmaceuticals Find the stock by name or ticker symbol: ALXN. Research its history to confirm it's a solid investment against your financial goals.
- Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Alexion Pharmaceuticals reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
- Decide on how many to buy. At last close price of USD$113.57, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Alexion Pharmaceuticals, depending on your broker.
- Check in on your investment. Congratulations, you own a part of Alexion Pharmaceuticals. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.
What's in this guide?
- Alexion Pharmaceuticals shares summary
- Compare share dealing platforms
- Is Alexion Pharmaceuticals stock a buy or sell?
- Alexion Pharmaceuticals performance over time
- Can I short Alexion Pharmaceuticals shares?
- Is Alexion Pharmaceuticals suitable for ethical investing?
- Are Alexion Pharmaceuticals shares over-valued?
- Alexion Pharmaceuticals's financials
- How volatile are Alexion Pharmaceuticals shares?
- Does Alexion Pharmaceuticals pay a dividend?
- Have Alexion Pharmaceuticals shares ever split?
- Other common questions
How has coronavirus impacted Alexion Pharmaceuticals's share price?
Since the stock market crash in March caused by coronavirus, Alexion Pharmaceuticals's share price has had significant positive movement.
Its last market close was USD$113.57, which is 9.18% up on its pre-crash value of USD$103.14 and 56.28% up on the lowest point reached during the March crash when the shares fell as low as USD$72.67.
If you had bought USD$1,000 worth of Alexion Pharmaceuticals shares at the start of February 2020, those shares would have been worth USD$804.81 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$1,126.61.
Alexion Pharmaceuticals share price
Use our graph to track the performance of ALXN stocks over time.Alexion Pharmaceuticals shares at a glance
Information last updated 2020-09-14.
| Latest market close | USD$113.57 |
|---|---|
| 52-week range | USD$72.67 - USD$121.5 |
| 50-day moving average | USD$105.2994 |
| 200-day moving average | USD$102.8799 |
| Wall St. target price | USD$141.32 |
| PE ratio | 28.2693 |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | USD$3.808 |
Compare trading platforms
Compare special offers, low fees and a wide range of types of investments among top trading platforms.The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Alexion Pharmaceuticals stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Alexion Pharmaceuticals price performance over time
Historical closes compared with the last close of $113.57
| 1 week (2020-09-07) | N/A |
|---|---|
| 1 month (2020-08-14) | N/A |
| 3 months (2020-06-18) | -2.36% |
| 6 months (2020-03-14) | N/A |
| 1 year (2019-09-14) | N/A |
|---|---|
| 2 years (2018-09-14) | N/A |
| 3 years (2017-09-14) | N/A |
| 5 years (2015-09-14) | N/A |
Is Alexion Pharmaceuticals under- or over-valued?
Valuing Alexion Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Alexion Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Alexion Pharmaceuticals's P/E ratio
Alexion Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 28x. In other words, Alexion Pharmaceuticals shares trade at around 28x recent earnings.
That's comparable to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29).
Alexion Pharmaceuticals's PEG ratio
Alexion Pharmaceuticals's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.6965. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Alexion Pharmaceuticals's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Alexion Pharmaceuticals's EBITDA
Alexion Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$2.9 billion.
The EBITDA is a measure of a Alexion Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.
Alexion Pharmaceuticals financials
| Revenue TTM | USD$5.5 billion |
|---|---|
| Operating margin TTM | 46.4% |
| Gross profit TTM | USD$4.6 billion |
| Return on assets TTM | 10.27% |
| Return on equity TTM | 8.19% |
| Profit margin | 15.28% |
| Book value | $47.881 |
| Market capitalisation | USD$24.1 billion |
TTM: trailing 12 months
Shorting Alexion Pharmaceuticals shares
There are currently 4.8 million Alexion Pharmaceuticals shares held short by investors – that's known as Alexion Pharmaceuticals's "short interest". This figure is 8.6% up from 4.4 million last month.
There are a few different ways that this level of interest in shorting Alexion Pharmaceuticals shares can be evaluated.
Alexion Pharmaceuticals's "short interest ratio" (SIR)
Alexion Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Alexion Pharmaceuticals shares currently shorted divided by the average quantity of Alexion Pharmaceuticals shares traded daily (recently around 1.6 million). Alexion Pharmaceuticals's SIR currently stands at 3. In other words for every 100,000 Alexion Pharmaceuticals shares traded daily on the market, roughly 3000 shares are currently held short.
However Alexion Pharmaceuticals's short interest can also be evaluated against the total number of Alexion Pharmaceuticals shares, or, against the total number of tradable Alexion Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Alexion Pharmaceuticals's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Alexion Pharmaceuticals shares in existence, roughly 20 shares are currently held short) or 0.023% of the tradable shares (for every 100,000 tradable Alexion Pharmaceuticals shares, roughly 23 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Alexion Pharmaceuticals.
Find out more about how you can short Alexion Pharmaceuticals stock.
Alexion Pharmaceuticals's environmental, social and governance track record
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Alexion Pharmaceuticals.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Alexion Pharmaceuticals's total ESG risk score
Total ESG risk: 32.02
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Alexion Pharmaceuticals's overall score of 32.02 (as at 08/01/2020) is nothing to write home about – landing it in it in the 42nd percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Alexion Pharmaceuticals is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Alexion Pharmaceuticals's environmental score
Environmental score: 8.12/100
Alexion Pharmaceuticals's environmental score of 8.12 puts it squarely in the 9th percentile of companies rated in the same sector. This could suggest that Alexion Pharmaceuticals is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Alexion Pharmaceuticals's social score
Social score: 25.12/100
Alexion Pharmaceuticals's social score of 25.12 puts it squarely in the 9th percentile of companies rated in the same sector. This could suggest that Alexion Pharmaceuticals is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Alexion Pharmaceuticals's governance score
Governance score: 11.78/100
Alexion Pharmaceuticals's governance score puts it squarely in the 9th percentile of companies rated in the same sector. That could suggest that Alexion Pharmaceuticals is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Alexion Pharmaceuticals's controversy score
Controversy score: 2/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Alexion Pharmaceuticals scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that Alexion Pharmaceuticals has, for the most part, managed to keep its nose clean.
Environmental, social, and governance (ESG) summary
Alexion Pharmaceuticals, Inc was last rated for ESG on: 2020-08-01.
| Total ESG score | 32.02 |
|---|---|
| Total ESG percentile | 41.58 |
| Environmental score | 8.12 |
| Environmental score percentile | 9 |
| Social score | 25.12 |
| Social score percentile | 9 |
| Governance score | 11.78 |
| Governance score percentile | 9 |
| Level of controversy | 2 |
Alexion Pharmaceuticals share dividends
We're not expecting Alexion Pharmaceuticals to pay a dividend over the next 12 months.
Have Alexion Pharmaceuticals's shares ever split?
Alexion Pharmaceuticals's shares were split on a 2:1 basis on 23 May 2011. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Alexion Pharmaceuticals shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Alexion Pharmaceuticals shares which in turn could have impacted Alexion Pharmaceuticals's share price.
Alexion Pharmaceuticals share price volatility
Over the last 12 months, Alexion Pharmaceuticals's shares have ranged in value from as little as $72.67 up to $121.5. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Alexion Pharmaceuticals's is 1.3952. This would suggest that Alexion Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Alexion Pharmaceuticals overview
Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a C5 inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS); and SOLIRIS (eculizumab), a monoclonal antibody for the treatment of PNH, aHUS, generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). It also provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia; and Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency. In addition, the company is developing ALXN1210 (Intravenous) that is in Phase III clinical trials for the treatment of gMG and NMOSD; ALXN1210 (Subcutaneous), which is in Phase III clinical trials for PNH and aHUS; ALXN1810 (Subcutaneous) that is in Phase I clinical trial for renal diseases; and ALXN1720 (Subcutaneous), which is in Phase I clinical trial for the treatment of disease states involving dysregulated terminal complement activity. Further, it is developing ALXN1840 (WTX101) that is in Phase III clinical trials for the treatment of Wilson disease; and ALXN1830 and ABY-039, which are in Phase I clinical trials for neonatal Fc receptor. The company serves distributors, pharmacies, hospitals, hospital buying groups, and other healthcare providers in the United States and internationally. Alexion Pharmaceuticals, Inc. has collaboration and license agreement with Halozyme Therapeutics, Inc.; collaboration with Dicerna Pharmaceuticals, Inc. and Zealand Pharma A/S; strategic agreement with Caelum Biosciences, Inc.; agreement with Stealth BioTherapeutics Corp.; and a partnership with Affibody AB. The company was founded in 1992 and is headquartered in Boston, Massachusetts.
Frequently asked questions
Ask an Expert